Basel-based research institute excelling in chromatin biology, neural circuit mapping, and developmental epigenetics through ERC-funded principal investigator science.
FMI is a premier biomedical research institute in Basel, Switzerland, focused on understanding fundamental mechanisms of gene regulation, epigenetics, and neural circuit function. Their scientists investigate how chromatin structure controls gene expression, how neuronal circuits drive behavior and emotion, and how cells make fate decisions during development. The institute operates at the intersection of molecular biology and systems neuroscience, using advanced techniques like optogenetics, connectomics, and organoid models to bridge molecular mechanisms with organism-level function.
Core strength spanning projects like ReaDMe, CsnCRL, Totipotency, REpiReg, BioMeTRe, TF-bind Determinants, TFtoChromatin, and ChromDesign — covering DNA methylation readout, histone modifications, nucleosome dynamics, and transcription factor-chromatin interactions.
Major focus across Amygdala Circuits, Descent, MCircuits, Thalamic Circuits, Cortical circuits, MoThal, and RETMUS — mapping how brain circuits in the cortex, amygdala, brainstem, and basal ganglia control behavior, emotion, and motor execution.
Projects including Totipotency, CYCLODE, EpiCrest2Reg, and SymBreakOrganoid investigate how cells acquire identity during embryonic development, with growing use of organoid models.
Increasing emphasis on mathematical modeling and quantitative approaches seen in OPTiAGE (optimal control theory), PEP-NET (predictive epigenetics), and SymBreakOrganoid (cell-to-cell variability quantification).
Participation in UbiCODE training network on ubiquitin code and CsnCRL project on cullin E3 ligase regulation, connecting protein degradation pathways to drug target identification.
Recent projects SymBreakOrganoid and related work signal growing investment in organoid-based experimental systems for studying development and disease.
In the early H2020 period (2015–2018), FMI's portfolio centered on chromatin and epigenetic mechanisms — transcription factor binding, DNA methylation, nucleosome dynamics — alongside foundational neuroscience using zebrafish and simple circuit models. From 2018 onward, their neuroscience work expanded dramatically into mammalian systems neuroscience: cortical processing, amygdala-driven emotion, brainstem motor pathways, and basal ganglia circuits, all enabled by optogenetics. Simultaneously, their developmental biology line matured toward organoid models and quantitative approaches, suggesting a strategic shift from purely molecular questions toward integrated, systems-level understanding of brain function and tissue development.
FMI is moving toward circuit-level neuroscience with quantitative and organoid-based approaches — future partners should expect projects combining optogenetics, computational modeling, and tissue engineering.
FMI overwhelmingly leads its own projects: 35 of 45 projects (78%) are self-coordinated, almost all funded through ERC grants (Advanced and Starting) and Marie Curie fellowships — instruments awarded to individual principal investigators rather than large consortia. Their 10 participations tend to be in structured training networks (MSCA-ITN) or large-scale coordination actions. This profile reveals an institute of independent, PI-driven research groups that attract top individual funding rather than an organization that builds or joins large multi-partner consortia.
FMI has collaborated with 72 unique partners across 18 countries, reflecting broad European reach despite being a relatively small, PI-driven institute. Their network is built primarily through training networks and multi-site ERC collaborations rather than repeated partnerships with the same institutions.
FMI combines world-class chromatin biology with deep systems neuroscience under one roof — a rare pairing that enables them to connect molecular epigenetic mechanisms directly to brain circuit function and behavior. As a Novartis-affiliated foundation in Basel, they operate with the scientific independence of an academic institute but with infrastructure and stability that few European research centers can match. Their exceptional ERC success rate (14 Advanced Grants, 5 Starting Grants) signals consistently top-tier principal investigators, making them a high-credibility partner for any consortium.
